Syncom Formulations (India) Limited has fixed September 23, 2026, as the record date for determining shareholder eligibility for a final dividend of ₹0.10 per equity share for the financial year ended March 31, 2026. This payout, representing a 10% distribution on the face value of ₹1 per share, is subject to approval by members at the company’s 38th Annual General Meeting (AGM). The announcement clarifies the timeline for investors seeking to retain or waive their dividend entitlement ahead of the upcoming meeting.

The 38th AGM is scheduled to be held on Wednesday, September 30, 2026, at 2:00 P.M., via Video Conferencing (VC) or Other Audio-Visual Means (OAVM), in compliance with the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Alongside the dividend approval, shareholders will also vote on the ratification of recent executive appointments, including Rinki Ankit Bankda as Whole-time Director and Rahul Vijay Bankda as Managing Director, following the resignation of previous top management effective August 11, 2026.

Shareholders who wish to voluntarily waive their dividend entitlement, either in full or in part, must submit a duly filled and signed Dividend Waiver Form to the company or its Registrar and Transfer Agent (RTA) on or before September 26, 2026. The form is available on the company’s website and can be submitted via email to finance@sfil.in or to the RTA at investor@ankitonline.com and compliance@ankitonline.com . This deadline ensures the company can process waivers before the dividend payment date.

Governance and Leadership Transition

The Board meeting held on August 11, 2026, concluded with significant changes to the executive team. Shri Kedarmal Shankarlal Bankda (Whole-time Director), Shri Vijay Shankarlal Bankda (Managing Director), and Shri Rahul Vijay Bankda (CFO) resigned from their positions effective August 11, 2026. To address these vacancies, the Board appointed Mrs. Rinki Ankit Bankda as Additional Director and Whole-time Director, and Shri Rahul Vijay Bankda as Additional Director and Managing Director, both effective August 12, 2026. Shri Ankur Vijay Bankda was appointed as the new CFO from the same date. These appointments are pending member approval at the AGM.

Additionally, the Board approved the appointment of Smt. Ruchi Jindal as a Woman Independent Director, effective June 29, 2027, subject to AGM approval. The company also finalized the appointment of a Cost Auditor and an Internal Auditor, with remuneration for the Cost Auditor requiring shareholder ratification. A Scrutinizer was appointed to oversee remote e-voting for the AGM.

Syncom Formulations Managing Director Vijay Shankarlal Bankda will step down from his role effective August 11, 2026, marking a significant leadership change for the pharmaceutical manufacturer. The resignation, received by the company on August 8, 2026, at 2:35 PM, is part of a planned succession strategy rather than a result of any dispute with the Board or management.

The company disclosed the development under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was submitted to both the BSE Limited and the National Stock Exchange of India Limited. Additionally, the disclosure aligns with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Leadership Transition Details

Vijay Shankarlal Bankda, who also serves as a promoter and founder of the company, tendered his resignation from the office of Managing Director and consequently from the Directorship. In his resignation letter, Bankda described his tenure as a privilege and highlighted the opportunity to work with the Board, employees, and stakeholders to strengthen the company’s long-term vision.

The key details of the resignation are outlined below:

Bankda confirmed that his decision was voluntary and did not arise from any disagreement with the Board, management, or any other material reason. He expressed confidence that the existing leadership team would continue to guide Syncom Formulations toward sustained growth.

Board Acknowledgement

The Board of Directors acknowledged the resignation and placed on record its appreciation for Bankda’s exemplary leadership, strategic vision, and dedicated service. Under his stewardship, the company reportedly strengthened its operations and governance standards while pursuing sustainable growth.

Vaishali Agrawal, Company Secretary and Compliance Officer, signed the disclosure on behalf of the company. The Board has requested the necessary statutory and regulatory formalities be completed to effectuate the change in leadership.